• Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Understand Public Information Act to protect records

Article

When companies interact with governmental bodies, issues related to the Public Information Act frequently arise. It is imperative for those companies to understand the Public Information Act as well as the internal procedures that may be developed to handle open records issues.

PUBLIC REQUEST

The Public Information Act allows members of the public to request access to information held by governmental entities. It is initiated when an individual makes an open records request to a governmental body. Under the act, all information held by governmental entities is subject to public disclosure unless the requested information falls within one of the act's specific exceptions to disclosure.

INTERNAL PROCESSES COMPANIES

When a company realizes that certain sensitive information will be in the government's possession, there are a number of steps it may take internally in order to provide as much protection as possible to proprietary and confidential documents.

One step is to carefully and clearly identify confidential documents contained in any submission to a governmental body. For example, a company may indicate in its cover letter to a governmental body that certain documents are confidential, and it also may choose to individually stamp or otherwise mark each of those documents as confidential. While this step will not automatically protect the confidentiality of the documents, it will provide additional support for the confidential nature of such information if an open records request is made for those documents. A company may also place highly confidential documents in a sealed envelope that is prominently marked "Proprietary and Confidential."

Another step that a company may take to protect sensitive information is to be certain that the governmental body requires the confidential information to be submitted in the first place.

Barry Senterfitt is a partner in the insurance industry practice of Akin Gump Strauss Hauer & Feld LLP in the firm's Austin, Texas, office.

Janet Farrer is an associate in the Austin office of Akin Gump Strauss Hauer & Feld.

Related Videos
Video 6 - "Navigating Insurance Coverage for Prescription Digital Therapeutics"
Video 5 - "FDA Approval Pathway for Prescription Digital Therapeutics"
Video 8 - "Gaps in Evidence Generation for Digital Therapeutics"
Video 7 - "Adoption Lessons For Payers"
Video 10 - "Managing Self Care"
Video 3 - "Embracing and Improving Access to Technology Tools"
Video 4 - "Assessing the Cost-Effectiveness of Prescription Digital Therapeutics "
© 2024 MJH Life Sciences

All rights reserved.